Life-Long Steroid Responsive Familial Myopathy With Docking Protein 7 Mutation

DOI Web Site 1 Citations
  • Shin J. Oh
    Department of Neurology, University of Alabama at Birmingham, Birmingham, AL; and
  • Peter H. King
    Department of Neurology, University of Alabama at Birmingham, Birmingham, AL; and
  • Alice Schindler
    Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD.

Abstract

<jats:title>Abstract</jats:title> <jats:p>Docking protein 7 (DOK7) congenital myasthenic syndrome (CMS) is characterized by limb-girdle weakness and lack of fluctuating fatigability simulating many familial myopathies. Albuterol is the first line of therapy in view of consistent improvement. Two brothers with progressive predominant biceps weakness for 1–3 years responded to prednisone treatment for 40–50 years. Various studies including muscle biopsy and many laboratory studies were unsuccessful for the definite diagnosis. Gene study, 40 years after the initial evaluation, confirmed the diagnosis of DOK7 CMS. These are the first reported cases of DOK7 CMS associated with a sustained benefit from corticosteroids.</jats:p>

Journal

Citations (1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top